Proteins > cAMP-specific 3',5'-cyclic phosphodiesterase 4D
Page last updated: 2024-08-07 17:02:56
cAMP-specific 3',5'-cyclic phosphodiesterase 4D
A 3,5-cyclic-AMP phosphodiesterase 4D that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q08499]
Synonyms
EC 3.1.4.53;
DPDE3;
PDE43
Research
Bioassay Publications (139)
Timeframe | Studies on this Protein(%) | All Drugs % |
pre-1990 | 7 (5.04) | 18.7374 |
1990's | 27 (19.42) | 18.2507 |
2000's | 44 (31.65) | 29.6817 |
2010's | 47 (33.81) | 24.3611 |
2020's | 14 (10.07) | 2.80 |
Compounds (92)
Drugs with Inhibition Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
theophylline | Homo sapiens (human) | IC50 | 637.0000 | 3 | 3 |
theophylline | Homo sapiens (human) | Ki | 530.0000 | 1 | 1 |
cilostamide | Homo sapiens (human) | IC50 | 50.0025 | 1 | 2 |
5,7-dimethoxycoumarin | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
clioquinol | Homo sapiens (human) | IC50 | 10.0000 | 2 | 2 |
denbufylline | Homo sapiens (human) | IC50 | 0.0851 | 2 | 2 |
dipyridamole | Homo sapiens (human) | IC50 | 2.1000 | 2 | 4 |
donepezil | Homo sapiens (human) | IC50 | 36.0000 | 1 | 1 |
9-(2-hydroxy-3-nonyl)adenine | Homo sapiens (human) | IC50 | 66.9333 | 1 | 3 |
etazolate | Homo sapiens (human) | IC50 | 0.3900 | 1 | 1 |
fluoxetine | Homo sapiens (human) | Ki | 1.5600 | 1 | 1 |
ibudilast | Homo sapiens (human) | IC50 | 0.1660 | 2 | 2 |
amrinone | Homo sapiens (human) | IC50 | 113.6000 | 4 | 5 |
1-methyl-3-isobutylxanthine | Homo sapiens (human) | IC50 | 45.6667 | 3 | 3 |
losartan | Homo sapiens (human) | IC50 | 26.0000 | 1 | 1 |
milrinone | Homo sapiens (human) | IC50 | 35.4333 | 2 | 3 |
nimodipine | Homo sapiens (human) | IC50 | 7.1500 | 1 | 1 |
papaverine | Homo sapiens (human) | IC50 | 13.2000 | 2 | 2 |
pentoxifylline | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone | Homo sapiens (human) | IC50 | 18.9333 | 2 | 3 |
rolipram | Homo sapiens (human) | IC50 | 15.8851 | 101 | 113 |
rolipram | Homo sapiens (human) | Ki | 1.4418 | 18 | 22 |
streptonigrin | Homo sapiens (human) | IC50 | 1.8700 | 1 | 1 |
thalidomide | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
tofisopam | Homo sapiens (human) | IC50 | 0.9000 | 1 | 0 |
trequinsin | Homo sapiens (human) | IC50 | 1.4334 | 2 | 3 |
zardaverine | Homo sapiens (human) | IC50 | 50.1985 | 11 | 21 |
9-benzyladenine | Homo sapiens (human) | IC50 | 160.0000 | 1 | 1 |
8-bromo cyclic adenosine monophosphate | Homo sapiens (human) | IC50 | 18.4667 | 2 | 3 |
enoximone | Homo sapiens (human) | IC50 | 52.6333 | 3 | 3 |
imazodan | Homo sapiens (human) | IC50 | 6.0000 | 1 | 1 |
tolafentrine | Homo sapiens (human) | IC50 | 0.0300 | 1 | 0 |
nitraquazone | Homo sapiens (human) | IC50 | 0.0500 | 1 | 1 |
cipamfylline | Homo sapiens (human) | IC50 | 1.9000 | 1 | 1 |
cipamfylline | Homo sapiens (human) | Ki | 21.0000 | 1 | 1 |
ethyl 3-amino-1h-pyrazole-4-carboxylate | Homo sapiens (human) | IC50 | 200.0000 | 1 | 2 |
8-((4-chlorophenyl)thio)cyclic-3',5'-amp | Homo sapiens (human) | IC50 | 81.3333 | 2 | 3 |
8-thio-benzyl cyclic amp | Homo sapiens (human) | IC50 | 29.0000 | 2 | 3 |
8-chloro-cyclic adenosine monophosphate | Homo sapiens (human) | IC50 | 34.3333 | 2 | 3 |
tadalafil | Homo sapiens (human) | IC50 | 68.0274 | 5 | 15 |
4-phenylpyrrolidone-2 | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 2 |
cdp 840 | Homo sapiens (human) | IC50 | 0.1029 | 7 | 7 |
7-benzylamino-6-chloro-2-piperazino-4-pyrrolidinopteridine | Homo sapiens (human) | IC50 | 0.0160 | 1 | 1 |
9-(2-hydroxy-3-nonyl)adenine | Homo sapiens (human) | Ki | 200.0000 | 1 | 1 |
9-(2-hydroxy-3-nonyl)adenine | Homo sapiens (human) | IC50 | 16.0000 | 1 | 1 |
cilomilast | Homo sapiens (human) | IC50 | 14.7349 | 25 | 37 |
cilomilast | Homo sapiens (human) | Ki | 0.0380 | 2 | 2 |
rp 73401 | Homo sapiens (human) | IC50 | 11.8692 | 20 | 30 |
rp 73401 | Homo sapiens (human) | Ki | 0.0011 | 6 | 6 |
moracin c | Homo sapiens (human) | IC50 | 26.0000 | 1 | 1 |
(+)-rolipram | Homo sapiens (human) | IC50 | 1.1905 | 4 | 4 |
n(6)-benzyl-cyclic adenosine 5'-monophosphate | Homo sapiens (human) | IC50 | 68.0000 | 2 | 3 |
moracin m | Homo sapiens (human) | IC50 | 2.9050 | 2 | 2 |
cocaine | Homo sapiens (human) | Ki | 1.1150 | 1 | 1 |
rolipram | Homo sapiens (human) | IC50 | 0.4422 | 6 | 6 |
mesopram | Homo sapiens (human) | IC50 | 1.1000 | 1 | 0 |
roflumilast | Homo sapiens (human) | IC50 | 44.3911 | 19 | 27 |
cyclic nucleotide phosphodiesterases, type 4 | Homo sapiens (human) | IC50 | 0.0250 | 2 | 3 |
eggmanone | Homo sapiens (human) | IC50 | 0.3800 | 1 | 1 |
3-(n,n-dimethylsulfonamido)-4-methyl-nitrobenzene | Homo sapiens (human) | IC50 | 1.2800 | 1 | 1 |
4,5-dihydro-6-(4-(imidazol-1-yl)phenyl)-5-methyl-3(2h)-pyridazinone | Homo sapiens (human) | Ki | 50.0000 | 4 | 8 |
tetomilast | Homo sapiens (human) | IC50 | 0.0720 | 2 | 1 |
mangostin | Homo sapiens (human) | IC50 | 1.3100 | 1 | 1 |
morusin | Homo sapiens (human) | IC50 | 0.9000 | 1 | 1 |
indolidan | Homo sapiens (human) | IC50 | 0.1500 | 1 | 1 |
cudraflavone c | Homo sapiens (human) | IC50 | 0.2600 | 1 | 1 |
fosbretabulin | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
9-Hydroxycalabaxanthone | Homo sapiens (human) | IC50 | 0.4200 | 2 | 2 |
sch 351591 | Homo sapiens (human) | IC50 | 0.0600 | 2 | 2 |
rs 14203 | Homo sapiens (human) | IC50 | 0.0050 | 2 | 2 |
gsk 256066 | Homo sapiens (human) | IC50 | 0.0000 | 2 | 2 |
ci 1044 | Homo sapiens (human) | IC50 | 0.2700 | 1 | 1 |
l-454,560 | Homo sapiens (human) | IC50 | 0.0010 | 7 | 7 |
t 1032 | Homo sapiens (human) | IC50 | 3.3000 | 1 | 1 |
l-826,141 | Homo sapiens (human) | IC50 | 0.0024 | 1 | 0 |
4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)-piperidine hydrogen chloride | Homo sapiens (human) | Ki | 1.0000 | 1 | 1 |
8-(methylthio)cyclic 3',5'-adenosine monophosphate | Homo sapiens (human) | IC50 | 39.0000 | 2 | 3 |
licoflavone c | Homo sapiens (human) | IC50 | 0.6300 | 1 | 1 |
oglemilast | Homo sapiens (human) | IC50 | 0.1660 | 1 | 0 |
apremilast | Homo sapiens (human) | IC50 | 0.1234 | 8 | 8 |
f-amidine | Homo sapiens (human) | IC50 | 110.8000 | 2 | 2 |
8-benzylthio-n(6)-n-butyladenosine cyclic-3,5'-monophosphate | Homo sapiens (human) | IC50 | 40.0000 | 2 | 3 |
lyoniside | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
pf 04217903 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
3-(2,5-dimethoxyphenyl)-6-(3,4-dimethoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine | Homo sapiens (human) | IC50 | 5.0246 | 2 | 2 |
n-alpha-benzoyl-n5-(2-chloro-1-iminoethyl)-l-ornithine amide | Homo sapiens (human) | IC50 | 5.9000 | 1 | 1 |
nitd 609 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
an2728 | Homo sapiens (human) | IC50 | 0.3270 | 5 | 5 |
bms-911543 | Homo sapiens (human) | IC50 | 5.6000 | 1 | 1 |
d159687 | Homo sapiens (human) | IC50 | 0.0270 | 1 | 1 |
chf6001 | Homo sapiens (human) | IC50 | 0.0000 | 3 | 3 |
sildenafil | Homo sapiens (human) | IC50 | 21.4321 | 12 | 22 |
zaprinast | Homo sapiens (human) | IC50 | 24.3333 | 3 | 3 |
zaprinast | Homo sapiens (human) | Ki | 39.6900 | 4 | 8 |
vardenafil | Homo sapiens (human) | IC50 | 6.6668 | 3 | 12 |
Imidazosagatriazinone | Homo sapiens (human) | IC50 | 0.5000 | 1 | 1 |
pelrinone | Homo sapiens (human) | IC50 | 4.0000 | 1 | 1 |
lixazinone | Homo sapiens (human) | IC50 | 0.0060 | 1 | 1 |
Drugs with Activation Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
rolipram | Homo sapiens (human) | EC50 | 1.1000 | 1 | 1 |
Drugs with Other Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
rolipram | Homo sapiens (human) | Log IC50 | 0.0064 | 1 | 1 |
Advances in the Development of Phosphodiesterase-4 Inhibitors.Journal of medicinal chemistry, , 10-08, Volume: 63, Issue:19, 2020
Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines.Journal of medicinal chemistry, , Sep-26, Volume: 40, Issue:20, 1997
2-(beta-Arylethylamino)- and 4-(beta-arylethylamino)quinazolines as phosphodiesterase inhibitors.Journal of medicinal chemistry, , Volume: 28, Issue:1, 1985
Substituted 6,7-dihydroimidazo[1,2-a]purin-9(4H)-ones.Journal of medicinal chemistry, , Volume: 23, Issue:11, 1980
Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.European journal of medicinal chemistry, , Feb-01, Volume: 163, 2019
Design, Synthesis, and Evaluation of Orally Available Clioquinol-Moracin M Hybrids as Multitarget-Directed Ligands for Cognitive Improvement in a Rat Model of Neurodegeneration in Alzheimer's Disease.Journal of medicinal chemistry, , Nov-12, Volume: 58, Issue:21, 2015
Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers.Journal of medicinal chemistry, , May-23, Volume: 45, Issue:11, 2002
Novel and selective calcitonin-inducing agents.Journal of medicinal chemistry, , Mar-23, Volume: 43, Issue:6, 2000
Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.The Journal of biological chemistry, , Apr-06, Volume: 287, Issue:15, 2012
2-Substituted-4-methoxybenzimidazole-based PDE4 inhibitors.Bioorganic & medicinal chemistry letters, , Oct-06, Volume: 8, Issue:19, 1998
Advances in the Development of Phosphodiesterase-4 Inhibitors.Journal of medicinal chemistry, , 10-08, Volume: 63, Issue:19, 2020
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.Journal of medicinal chemistry, , Sep-25, Volume: 51, Issue:18, 2008
Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines.Journal of medicinal chemistry, , Sep-26, Volume: 40, Issue:20, 1997
New 5H-pyridazino[4,5-b]indole derivatives. Synthesis and studies as inhibitors of blood platelet aggregation and inotropics.Journal of medicinal chemistry, , Volume: 34, Issue:10, 1991
Synthesis and cardiotonic activity of novel biimidazoles.Journal of medicinal chemistry, , Volume: 33, Issue:1, 1990
Synthesis and biological evaluation of pyridazinone derivatives as potential anti-inflammatory agents.European journal of medicinal chemistry, , Feb-25, Volume: 146, 2018
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.Journal of medicinal chemistry, , Aug-11, Volume: 59, Issue:15, 2016
Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.The Journal of biological chemistry, , Apr-06, Volume: 287, Issue:15, 2012
Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.The Journal of biological chemistry, , Apr-06, Volume: 287, Issue:15, 2012
Cardiotonic agents. 2. (Imidazolyl)aroylimidazolones, highly potent and selective positive inotropic agents.Journal of medicinal chemistry, , Volume: 30, Issue:8, 1987
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.Journal of medicinal chemistry, , Aug-11, Volume: 59, Issue:15, 2016
Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.The Journal of biological chemistry, , Apr-06, Volume: 287, Issue:15, 2012
Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines.Journal of medicinal chemistry, , Sep-26, Volume: 40, Issue:20, 1997
Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues.Journal of medicinal chemistry, , Volume: 32, Issue:7, 1989
Discovery of novel 2,3-dihydro-1H-inden-1-ones as dual PDE4/AChE inhibitors with more potency against neuroinflammation for the treatment of Alzheimer's disease.European journal of medicinal chemistry, , Aug-05, Volume: 238, 2022
[no title available]Journal of medicinal chemistry, , 09-23, Volume: 64, Issue:18, 2021
New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.European journal of medicinal chemistry, , Jan-01, Volume: 209, 2021
Synthesis and bioactivity of phenyl substituted furan and oxazole carboxylic acid derivatives as potential PDE4 inhibitors.European journal of medicinal chemistry, , Dec-01, Volume: 207, 2020
Synthesis and SAR Studies of 1ACS medicinal chemistry letters, , Oct-08, Volume: 11, Issue:10, 2020
Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.European journal of medicinal chemistry, , Oct-15, Volume: 204, 2020
Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.Journal of medicinal chemistry, , 03-26, Volume: 63, Issue:6, 2020
InClEuropean journal of medicinal chemistry, , Jul-15, Volume: 174, 2019
Dual functional cholinesterase and PDE4D inhibitors for the treatment of Alzheimer's disease: Design, synthesis and evaluation of tacrine-pyrazolo[3,4-b]pyridine hybrids.Bioorganic & medicinal chemistry letters, , 08-15, Volume: 29, Issue:16, 2019
Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.European journal of medicinal chemistry, , Feb-01, Volume: 163, 2019
Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.Journal of medicinal chemistry, , 06-13, Volume: 62, Issue:11, 2019
[no title available]Journal of natural products, , 07-26, Volume: 82, Issue:7, 2019
Discovery of novel inhibitors of phosphodiesterase 4 with 1-phenyl-3,4-dihydroisoquinoline scaffold: Structure-based drug design and fragment identification.Bioorganic & medicinal chemistry letters, , 11-15, Volume: 29, Issue:22, 2019
Tetrahydroquinoline and tetrahydroisoquinoline derivatives as potential selective PDE4B inhibitors.Bioorganic & medicinal chemistry letters, , 10-15, Volume: 28, Issue:19, 2018
Prenylated flavonoids as potent phosphodiesterase-4 inhibitors from Morus alba: Isolation, modification, and structure-activity relationship study.European journal of medicinal chemistry, , Jan-20, Volume: 144, 2018
Synthesis and bioactivity of 3,5-dimethylpyrazole derivatives as potential PDE4 inhibitors.Bioorganic & medicinal chemistry letters, , 10-15, Volume: 28, Issue:19, 2018
Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis.European journal of medicinal chemistry, , Feb-10, Volume: 145, 2018
Structure-based design and structure-activity relationships of 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.Bioorganic & medicinal chemistry letters, , 04-15, Volume: 28, Issue:7, 2018
Rational design of conformationally constrained oxazolidinone-fused 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.Bioorganic & medicinal chemistry, , 10-15, Volume: 25, Issue:20, 2017
[no title available]Bioorganic & medicinal chemistry, , 03-15, Volume: 25, Issue:6, 2017
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.Journal of medicinal chemistry, , Aug-11, Volume: 59, Issue:15, 2016
Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.European journal of medicinal chemistry, , Nov-29, Volume: 124, 2016
Design, Synthesis, and Evaluation of Orally Available Clioquinol-Moracin M Hybrids as Multitarget-Directed Ligands for Cognitive Improvement in a Rat Model of Neurodegeneration in Alzheimer's Disease.Journal of medicinal chemistry, , Nov-12, Volume: 58, Issue:21, 2015
Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships.Bioorganic & medicinal chemistry, , Nov-15, Volume: 23, Issue:22, 2015
Synthesis, biological evaluation, and molecular modeling of new 3-(cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) Oxime (GEBR-7b) related phosphodiesterase 4D (PDE4D) inhibitors.Journal of medicinal chemistry, , Aug-28, Volume: 57, Issue:16, 2014
Novel Roflumilast analogs as soft PDE4 inhibitors.Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 24, Issue:18, 2014
Prenylated coumarins: natural phosphodiesterase-4 inhibitors from Toddalia asiatica.Journal of natural products, , Apr-25, Volume: 77, Issue:4, 2014
Prostaglandin Derivatives: Nonaromatic Phosphodiesterase-4 Inhibitors from the Soft Coral Sarcophyton ehrenbergi.Journal of natural products, , Aug-22, Volume: 77, Issue:8, 2014
Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors.Journal of medicinal chemistry, , Oct-23, Volume: 57, Issue:20, 2014
Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.Journal of medicinal chemistry, , Sep-13, Volume: 55, Issue:17, 2012
Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.The Journal of biological chemistry, , Apr-06, Volume: 287, Issue:15, 2012
Identification of chalcones as potent and selective PDE5A1 inhibitors.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 22, Issue:12, 2012
Synthesis and biological activity of pyrido[3',2':4,5]thieno[3,2-d]pyrimidines as phosphodiesterase type 4 inhibitors.Journal of medicinal chemistry, , Oct-14, Volume: 53, Issue:19, 2010
In silico search for multi-target anti-inflammatories in Chinese herbs and formulas.Bioorganic & medicinal chemistry, , Mar-15, Volume: 18, Issue:6, 2010
New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isoforms.Journal of medicinal chemistry, , Nov-12, Volume: 52, Issue:21, 2009
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.Bioorganic & medicinal chemistry letters, , Jul-01, Volume: 19, Issue:13, 2009
Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.Bioorganic & medicinal chemistry letters, , Apr-15, Volume: 19, Issue:8, 2009
Design, synthesis, and structure-activity relationship, molecular modeling, and NMR studies of a series of phenyl alkyl ketones as highly potent and selective phosphodiesterase-4 inhibitors.Journal of medicinal chemistry, , Dec-25, Volume: 51, Issue:24, 2008
Identification of a potent new chemotype for the selective inhibition of PDE4.Bioorganic & medicinal chemistry letters, , Feb-15, Volume: 18, Issue:4, 2008
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.Journal of medicinal chemistry, , Sep-25, Volume: 51, Issue:18, 2008
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.Bioorganic & medicinal chemistry letters, , Volume: 16, Issue:3, 2006
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.Journal of medicinal chemistry, , May-19, Volume: 48, Issue:10, 2005
8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyl-adenine: highly potent and selective PDE4 inhibitors.Journal of medicinal chemistry, , Feb-24, Volume: 48, Issue:4, 2005
Structural basis for the activity of drugs that inhibit phosphodiesterases.Structure (London, England : 1993), , Volume: 12, Issue:12, 2004
Synthesis and biological activities of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives as PDE4 inhibitors.Bioorganic & medicinal chemistry letters, , Jul-21, Volume: 13, Issue:14, 2003
7-Methoxyfuro[2,3-c]pyridine-4-carboxamides as PDE4 inhibitors: a potential treatment for asthma.Bioorganic & medicinal chemistry letters, , Feb-11, Volume: 12, Issue:3, 2002
8-Methoxyquinoline-5-carboxamides as PDE4 inhibitors: a potential treatment for asthma.Bioorganic & medicinal chemistry letters, , Jun-17, Volume: 12, Issue:12, 2002
Novel selective phosphodiesterase (PDE4) inhibitors. 4. Resolution, absolute configuration, and PDE4 inhibitory activity of cis-tetra- and cis-hexahydrophthalazinones.Journal of medicinal chemistry, , Jun-06, Volume: 45, Issue:12, 2002
Phthalazine PDE4 inhibitors. Part 3: the synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor.Bioorganic & medicinal chemistry letters, , Jan-07, Volume: 12, Issue:1, 2002
Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives.Bioorganic & medicinal chemistry letters, , Jan-08, Volume: 11, Issue:1, 2001
Synthesis and biological evaluation of 2,5-dihydropyrazol.Bioorganic & medicinal chemistry letters, , Dec-04, Volume: 10, Issue:23, 2000
Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.Journal of medicinal chemistry, , Dec-14, Volume: 43, Issue:25, 2000
The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I.Bioorganic & medicinal chemistry letters, , Oct-02, Volume: 10, Issue:19, 2000
7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma.Bioorganic & medicinal chemistry letters, , Sep-18, Volume: 10, Issue:18, 2000
Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors.Journal of medicinal chemistry, , Feb-24, Volume: 43, Issue:4, 2000
Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.Journal of medicinal chemistry, , Mar-25, Volume: 42, Issue:6, 1999
The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I.Bioorganic & medicinal chemistry letters, , Jul-21, Volume: 8, Issue:14, 1998
Orally active indole N-oxide PDE4 inhibitors.Bioorganic & medicinal chemistry letters, , Nov-03, Volume: 8, Issue:21, 1998
7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridines as novel inhibitors of human eosinophil phosphodiesterase.Journal of medicinal chemistry, , Jun-18, Volume: 41, Issue:13, 1998
Quaternary substituted PDE4 inhibitors I: the synthesis and in vitro evaluation of a novel series of oxindoles.Bioorganic & medicinal chemistry letters, , Jan-20, Volume: 8, Issue:2, 1998
Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.Journal of medicinal chemistry, , Jan-29, Volume: 41, Issue:3, 1998
Aryl sulfonamides as selective PDE4 inhibitors.Bioorganic & medicinal chemistry letters, , Oct-06, Volume: 8, Issue:19, 1998
Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors.Journal of medicinal chemistry, , Oct-08, Volume: 41, Issue:21, 1998
Thalidomide analogs and PDE4 inhibition.Bioorganic & medicinal chemistry letters, , Oct-06, Volume: 8, Issue:19, 1998
Synthesis and evaluation of a novel series of phosphodiesterase IV inhibitors. A potential treatment for asthma.Bioorganic & medicinal chemistry letters, , Oct-06, Volume: 8, Issue:19, 1998
N-arylrolipram derivatives as potent and selective PDE4 inhibitors.Bioorganic & medicinal chemistry letters, , Nov-17, Volume: 8, Issue:22, 1998
9-Benzyladenines: potent and selective cAMP phosphodiesterase inhibitors.Journal of medicinal chemistry, , Jun-06, Volume: 40, Issue:12, 1997
Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors.Journal of medicinal chemistry, , May-09, Volume: 40, Issue:10, 1997
Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.Journal of medicinal chemistry, , Jan-05, Volume: 39, Issue:1, 1996
Introduction of a conformational switching element on a pyrrolidine ring. Synthesis and evaluation of (R*,R*)-(+/-)-methyl 3-acetyl-4-[3- (cyclopentyloxy)-4-methoxyphenyl]-3-methyl-1-pyrrolidinecarboxylate, a potent and selective inhibitor of cAMP-specifiJournal of medicinal chemistry, , Dec-22, Volume: 38, Issue:26, 1995
Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues.Journal of medicinal chemistry, , May-27, Volume: 37, Issue:11, 1994
New bronchodilators. 3. Imidazo[4,5-c][1,8]naphthyridin-4(5H)-ones.Journal of medicinal chemistry, , Dec-25, Volume: 35, Issue:26, 1992
Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues.Journal of medicinal chemistry, , Volume: 32, Issue:7, 1989
Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.The Journal of biological chemistry, , Apr-06, Volume: 287, Issue:15, 2012
Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues.Journal of medicinal chemistry, , Volume: 32, Issue:7, 1989
Advances in the Development of Phosphodiesterase-4 Inhibitors.Journal of medicinal chemistry, , 10-08, Volume: 63, Issue:19, 2020
Synthesis and biological evaluation of pyridazinone derivatives as potential anti-inflammatory agents.European journal of medicinal chemistry, , Feb-25, Volume: 146, 2018
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.Journal of medicinal chemistry, , Aug-11, Volume: 59, Issue:15, 2016
Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.Journal of medicinal chemistry, , Sep-13, Volume: 55, Issue:17, 2012
Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.The Journal of biological chemistry, , Apr-06, Volume: 287, Issue:15, 2012
In silico search for multi-target anti-inflammatories in Chinese herbs and formulas.Bioorganic & medicinal chemistry, , Mar-15, Volume: 18, Issue:6, 2010
Structural basis for the activity of drugs that inhibit phosphodiesterases.Structure (London, England : 1993), , Volume: 12, Issue:12, 2004
Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents.Journal of medicinal chemistry, , May-08, Volume: 46, Issue:10, 2003
Novel selective PDE4 inhibitors. 1. Synthesis, structure-activity relationships, and molecular modeling of 4-(3,4-dimethoxyphenyl)-2H-phthalazin-1-ones and analogues.Journal of medicinal chemistry, , Aug-02, Volume: 44, Issue:16, 2001
[no title available],
Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.Journal of medicinal chemistry, , 05-23, Volume: 62, Issue:10, 2019
Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease.European journal of medicinal chemistry, , Volume: 60, 2013
Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.Bioorganic & medicinal chemistry letters, , May-02, Volume: 15, Issue:9, 2005
Structural basis for the activity of drugs that inhibit phosphodiesterases.Structure (London, England : 1993), , Volume: 12, Issue:12, 2004
The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues.Journal of medicinal chemistry, , Oct-09, Volume: 46, Issue:21, 2003
Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.Bioorganic & medicinal chemistry letters, , Dec-01, Volume: 15, Issue:23, 2005
Novel selective phosphodiesterase (PDE4) inhibitors. 4. Resolution, absolute configuration, and PDE4 inhibitory activity of cis-tetra- and cis-hexahydrophthalazinones.Journal of medicinal chemistry, , Jun-06, Volume: 45, Issue:12, 2002
Novel selective PDE4 inhibitors. 3. In vivo antiinflammatory activity of a new series of N-substituted cis-tetra- and cis-hexahydrophthalazinones.Journal of medicinal chemistry, , Jun-06, Volume: 45, Issue:12, 2002
Quaternary substituted PDE4 inhibitors I: the synthesis and in vitro evaluation of a novel series of oxindoles.Bioorganic & medicinal chemistry letters, , Jan-20, Volume: 8, Issue:2, 1998
7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridines as novel inhibitors of human eosinophil phosphodiesterase.Journal of medicinal chemistry, , Jun-18, Volume: 41, Issue:13, 1998
Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.European journal of medicinal chemistry, , Oct-15, Volume: 204, 2020
Advances in the Development of Phosphodiesterase-4 Inhibitors.Journal of medicinal chemistry, , 10-08, Volume: 63, Issue:19, 2020
Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.Journal of medicinal chemistry, , 06-13, Volume: 62, Issue:11, 2019
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.Journal of medicinal chemistry, , Aug-11, Volume: 59, Issue:15, 2016
In silico search for multi-target anti-inflammatories in Chinese herbs and formulas.Bioorganic & medicinal chemistry, , Mar-15, Volume: 18, Issue:6, 2010
Discovery of selective PDE4B inhibitors.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 19, Issue:12, 2009
SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.Journal of medicinal chemistry, , Jan-25, Volume: 50, Issue:2, 2007
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.Journal of medicinal chemistry, , May-19, Volume: 48, Issue:10, 2005
Structural basis for the activity of drugs that inhibit phosphodiesterases.Structure (London, England : 1993), , Volume: 12, Issue:12, 2004
Orally active PDE4 inhibitors with therapeutic potential.Bioorganic & medicinal chemistry letters, , Mar-08, Volume: 14, Issue:5, 2004
Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents.Journal of medicinal chemistry, , May-08, Volume: 46, Issue:10, 2003
Novel selective phosphodiesterase (PDE4) inhibitors. 4. Resolution, absolute configuration, and PDE4 inhibitory activity of cis-tetra- and cis-hexahydrophthalazinones.Journal of medicinal chemistry, , Jun-06, Volume: 45, Issue:12, 2002
Novel selective PDE4 inhibitors. 3. In vivo antiinflammatory activity of a new series of N-substituted cis-tetra- and cis-hexahydrophthalazinones.Journal of medicinal chemistry, , Jun-06, Volume: 45, Issue:12, 2002
Phthalazine PDE4 inhibitors. Part 3: the synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor.Bioorganic & medicinal chemistry letters, , Jan-07, Volume: 12, Issue:1, 2002
Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor.Bioorganic & medicinal chemistry letters, , Jan-21, Volume: 12, Issue:2, 2002
Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones.Journal of medicinal chemistry, , Aug-02, Volume: 44, Issue:16, 2001
Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives.Bioorganic & medicinal chemistry letters, , Jan-08, Volume: 11, Issue:1, 2001
Novel selective PDE4 inhibitors. 1. Synthesis, structure-activity relationships, and molecular modeling of 4-(3,4-dimethoxyphenyl)-2H-phthalazin-1-ones and analogues.Journal of medicinal chemistry, , Aug-02, Volume: 44, Issue:16, 2001
Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.Journal of medicinal chemistry, , Dec-14, Volume: 43, Issue:25, 2000
Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors.Journal of medicinal chemistry, , Feb-24, Volume: 43, Issue:4, 2000
7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridines as novel inhibitors of human eosinophil phosphodiesterase.Journal of medicinal chemistry, , Jun-18, Volume: 41, Issue:13, 1998
1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.Journal of medicinal chemistry, , Mar-12, Volume: 41, Issue:6, 1998
[no title available],
Advances in the Development of Phosphodiesterase-4 Inhibitors.Journal of medicinal chemistry, , 10-08, Volume: 63, Issue:19, 2020
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.Journal of medicinal chemistry, , Aug-11, Volume: 59, Issue:15, 2016
In silico search for multi-target anti-inflammatories in Chinese herbs and formulas.Bioorganic & medicinal chemistry, , Mar-15, Volume: 18, Issue:6, 2010
SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.Journal of medicinal chemistry, , Jan-25, Volume: 50, Issue:2, 2007
Structural basis for the activity of drugs that inhibit phosphodiesterases.Structure (London, England : 1993), , Volume: 12, Issue:12, 2004
Synthesis and biological activities of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives as PDE4 inhibitors.Bioorganic & medicinal chemistry letters, , Jul-21, Volume: 13, Issue:14, 2003
Phthalazine PDE4 inhibitors. Part 3: the synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor.Bioorganic & medicinal chemistry letters, , Jan-07, Volume: 12, Issue:1, 2002
Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives.Bioorganic & medicinal chemistry letters, , Jan-08, Volume: 11, Issue:1, 2001
The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I.Bioorganic & medicinal chemistry letters, , Oct-02, Volume: 10, Issue:19, 2000
Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.Journal of medicinal chemistry, , Oct-22, Volume: 41, Issue:22, 1998
Orally active indole N-oxide PDE4 inhibitors.Bioorganic & medicinal chemistry letters, , Nov-03, Volume: 8, Issue:21, 1998
The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I.Bioorganic & medicinal chemistry letters, , Jul-21, Volume: 8, Issue:14, 1998
7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridines as novel inhibitors of human eosinophil phosphodiesterase.Journal of medicinal chemistry, , Jun-18, Volume: 41, Issue:13, 1998
Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.Journal of medicinal chemistry, , Jan-29, Volume: 41, Issue:3, 1998
2-Substituted-4-methoxybenzimidazole-based PDE4 inhibitors.Bioorganic & medicinal chemistry letters, , Oct-06, Volume: 8, Issue:19, 1998
Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues.Journal of medicinal chemistry, , May-27, Volume: 37, Issue:11, 1994
[no title available],
Discovery and modelling studies of natural ingredients from Gaultheria yunnanensis (FRANCH.) against phosphodiesterase-4.European journal of medicinal chemistry, , May-23, Volume: 114, 2016
1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.Journal of medicinal chemistry, , Mar-12, Volume: 41, Issue:6, 1998
The crystal structure, absolute configuration, and phosphodiesterase inhibitory activity of (+)-1-(4-bromobenzyl)-4-(3-(cyclopentyloxy)- 4-methoxyphenyl)-pyrrolidin-2-one.Journal of medicinal chemistry, , Oct-29, Volume: 36, Issue:22, 1993
Design, Synthesis, and Evaluation of Orally Available Clioquinol-Moracin M Hybrids as Multitarget-Directed Ligands for Cognitive Improvement in a Rat Model of Neurodegeneration in Alzheimer's Disease.Journal of medicinal chemistry, , Nov-12, Volume: 58, Issue:21, 2015
Moracin M from Morus alba L. is a natural phosphodiesterase-4 inhibitor.Bioorganic & medicinal chemistry letters, , May-01, Volume: 22, Issue:9, 2012
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.Journal of medicinal chemistry, , Aug-11, Volume: 59, Issue:15, 2016
SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.Journal of medicinal chemistry, , Jan-25, Volume: 50, Issue:2, 2007
Novel selective PDE4 inhibitors. 3. In vivo antiinflammatory activity of a new series of N-substituted cis-tetra- and cis-hexahydrophthalazinones.Journal of medicinal chemistry, , Jun-06, Volume: 45, Issue:12, 2002
Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones.Journal of medicinal chemistry, , Aug-02, Volume: 44, Issue:16, 2001
1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.Journal of medicinal chemistry, , Mar-12, Volume: 41, Issue:6, 1998
The crystal structure, absolute configuration, and phosphodiesterase inhibitory activity of (+)-1-(4-bromobenzyl)-4-(3-(cyclopentyloxy)- 4-methoxyphenyl)-pyrrolidin-2-one.Journal of medicinal chemistry, , Oct-29, Volume: 36, Issue:22, 1993
Discovery and Structural Optimization of Toddacoumalone Derivatives as Novel PDE4 Inhibitors for the Topical Treatment of Psoriasis.Journal of medicinal chemistry, , 03-10, Volume: 65, Issue:5, 2022
Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.European journal of medicinal chemistry, , Oct-15, Volume: 204, 2020
Discovery and Early Clinical Development of Isobutyl 1-[8-Methoxy-5-(1-oxo-3Journal of medicinal chemistry, , 12-10, Volume: 63, Issue:23, 2020
Advances in the Development of Phosphodiesterase-4 Inhibitors.Journal of medicinal chemistry, , 10-08, Volume: 63, Issue:19, 2020
Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.Journal of medicinal chemistry, , 03-26, Volume: 63, Issue:6, 2020
Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.European journal of medicinal chemistry, , Feb-01, Volume: 163, 2019
Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.Journal of medicinal chemistry, , 06-13, Volume: 62, Issue:11, 2019
InClEuropean journal of medicinal chemistry, , Jul-15, Volume: 174, 2019
[no title available]European journal of medicinal chemistry, , Mar-25, Volume: 148, 2018
Structure-based design and structure-activity relationships of 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.Bioorganic & medicinal chemistry letters, , 04-15, Volume: 28, Issue:7, 2018
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.Journal of medicinal chemistry, , Aug-11, Volume: 59, Issue:15, 2016
Novel Roflumilast analogs as soft PDE4 inhibitors.Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 24, Issue:18, 2014
Moracin M from Morus alba L. is a natural phosphodiesterase-4 inhibitor.Bioorganic & medicinal chemistry letters, , May-01, Volume: 22, Issue:9, 2012
Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD.Bioorganic & medicinal chemistry letters, , Feb-15, Volume: 22, Issue:4, 2012
Synthesis and biological activity of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel and potent phosphodiesterase type 4 inhibitors.European journal of medicinal chemistry, , Volume: 46, Issue:10, 2011
Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.Journal of medicinal chemistry, , May-19, Volume: 48, Issue:10, 2005
Structural basis for the activity of drugs that inhibit phosphodiesterases.Structure (London, England : 1993), , Volume: 12, Issue:12, 2004
[no title available],
[no title available]Journal of medicinal chemistry, , 09-23, Volume: 64, Issue:18, 2021
Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.Journal of medicinal chemistry, , 03-26, Volume: 63, Issue:6, 2020
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.Journal of medicinal chemistry, , Sep-25, Volume: 51, Issue:18, 2008
Novel selective PDE4 inhibitors. 1. Synthesis, structure-activity relationships, and molecular modeling of 4-(3,4-dimethoxyphenyl)-2H-phthalazin-1-ones and analogues.Journal of medicinal chemistry, , Aug-02, Volume: 44, Issue:16, 2001
Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.Journal of medicinal chemistry, , Dec-14, Volume: 43, Issue:25, 2000
The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors.Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 20, Issue:18, 2010
Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.Bioorganic & medicinal chemistry letters, , Nov-15, Volume: 20, Issue:22, 2010
Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 19, Issue:17, 2009
Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.Bioorganic & medicinal chemistry letters, , Dec-01, Volume: 15, Issue:23, 2005
Diterpenoids from the Root Bark of Journal of natural products, , 04-24, Volume: 83, Issue:4, 2020
Advances in the Development of Phosphodiesterase-4 Inhibitors.Journal of medicinal chemistry, , 10-08, Volume: 63, Issue:19, 2020
Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.Journal of medicinal chemistry, , 03-26, Volume: 63, Issue:6, 2020
Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders.Journal of medicinal chemistry, , 05-23, Volume: 62, Issue:10, 2019
Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.Journal of medicinal chemistry, , 06-13, Volume: 62, Issue:11, 2019
InClEuropean journal of medicinal chemistry, , Jul-15, Volume: 174, 2019
Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.Bioorganic & medicinal chemistry letters, , Jul-01, Volume: 19, Issue:13, 2009
Identification of a potent new chemotype for the selective inhibition of PDE4.Bioorganic & medicinal chemistry letters, , Feb-15, Volume: 18, Issue:4, 2008
Discovery and Structural Optimization of Toddacoumalone Derivatives as Novel PDE4 Inhibitors for the Topical Treatment of Psoriasis.Journal of medicinal chemistry, , 03-10, Volume: 65, Issue:5, 2022
Advances in the Development of Phosphodiesterase-4 Inhibitors.Journal of medicinal chemistry, , 10-08, Volume: 63, Issue:19, 2020
Lead-like Drugs: A Perspective.Journal of medicinal chemistry, , 12-13, Volume: 61, Issue:23, 2018
Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.Bioorganic & medicinal chemistry letters, , Apr-15, Volume: 19, Issue:8, 2009
Advances in the Development of Phosphodiesterase-4 Inhibitors.Journal of medicinal chemistry, , 10-08, Volume: 63, Issue:19, 2020
Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases.Journal of medicinal chemistry, , Feb-13, Volume: 57, Issue:3, 2014
Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.Journal of medicinal chemistry, , 05-23, Volume: 62, Issue:10, 2019
Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease.European journal of medicinal chemistry, , Volume: 60, 2013
Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.The Journal of biological chemistry, , Apr-06, Volume: 287, Issue:15, 2012
Identification of chalcones as potent and selective PDE5A1 inhibitors.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 22, Issue:12, 2012
In silico search for multi-target anti-inflammatories in Chinese herbs and formulas.Bioorganic & medicinal chemistry, , Mar-15, Volume: 18, Issue:6, 2010
Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.Bioorganic & medicinal chemistry letters, , May-02, Volume: 15, Issue:9, 2005
Structural basis for the activity of drugs that inhibit phosphodiesterases.Structure (London, England : 1993), , Volume: 12, Issue:12, 2004
The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues.Journal of medicinal chemistry, , Oct-09, Volume: 46, Issue:21, 2003
The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues.Journal of medicinal chemistry, , Oct-09, Volume: 46, Issue:21, 2003
1,7- and 2,7-naphthyridine derivatives as potent and highly specific PDE5 inhibitors.Bioorganic & medicinal chemistry letters, , Jul-21, Volume: 13, Issue:14, 2003
Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors.Bioorganic & medicinal chemistry letters, , Mar-25, Volume: 12, Issue:6, 2002
Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives.Journal of medicinal chemistry, , Jun-21, Volume: 44, Issue:13, 2001
Identification of chalcones as potent and selective PDE5A1 inhibitors.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 22, Issue:12, 2012
8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyl-adenine: highly potent and selective PDE4 inhibitors.Journal of medicinal chemistry, , Feb-24, Volume: 48, Issue:4, 2005
The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues.Journal of medicinal chemistry, , Oct-09, Volume: 46, Issue:21, 2003
Inhibition of cyclic nucleotide phosphodiesterase by derivatives of 1,3-bis(cyclopropylmethyl)xanthine.Journal of medicinal chemistry, , Feb-18, Volume: 37, Issue:4, 1994
Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease.European journal of medicinal chemistry, , Volume: 60, 2013
Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.Bioorganic & medicinal chemistry letters, , May-02, Volume: 15, Issue:9, 2005
Structural basis for the activity of drugs that inhibit phosphodiesterases.Structure (London, England : 1993), , Volume: 12, Issue:12, 2004
Enables
This protein enables 14 target(s):
Target | Category | Definition |
3',5'-cyclic-nucleotide phosphodiesterase activity | molecular function | Catalysis of the reaction: a nucleoside 3',5'-cyclic phosphate + H2O = a nucleoside 5'-phosphate. [RHEA:14653] |
3',5'-cyclic-AMP phosphodiesterase activity | molecular function | Catalysis of the reaction: 3',5'-cyclic AMP + H2O = AMP + H+. [GOC:ai, RHEA:25277] |
calcium channel regulator activity | molecular function | Modulates the activity of a calcium channel. [GOC:mah] |
protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
enzyme binding | molecular function | Binding to an enzyme, a protein with catalytic activity. [GOC:jl] |
signaling receptor regulator activity | molecular function | Binds to and modulates the activity of a receptor. [GOC:ceb] |
cAMP binding | molecular function | Binding to cAMP, the nucleotide cyclic AMP (adenosine 3',5'-cyclophosphate). [GOC:ai] |
beta-2 adrenergic receptor binding | molecular function | Binding to a beta-2 adrenergic receptor. [GOC:mah, GOC:nln] |
transmembrane transporter binding | molecular function | Binding to a transmembrane transporter, a protein or protein complex that enables the transfer of a substance, usually a specific substance or a group of related substances, from one side of a membrane to the other. [GOC:BHF, GOC:jl, PMID:33199372] |
metal ion binding | molecular function | Binding to a metal ion. [GOC:ai] |
ATPase binding | molecular function | Binding to an ATPase, any enzyme that catalyzes the hydrolysis of ATP. [GOC:ai] |
scaffold protein binding | molecular function | Binding to a scaffold protein. Scaffold proteins are crucial regulators of many key signaling pathways. Although not strictly defined in function, they are known to interact and/or bind with multiple members of a signaling pathway, tethering them into complexes. [GOC:BHF, GOC:sjp, PMID:10433269, Wikipedia:Scaffold_protein] |
heterocyclic compound binding | molecular function | Binding to heterocyclic compound. [GOC:TermGenie] |
3',5'-cyclic-GMP phosphodiesterase activity | molecular function | Catalysis of the reaction: 3',5'-cyclic GMP + H2O = GMP + H+. [RHEA:16957] |
Located In
This protein is located in 4 target(s):
Target | Category | Definition |
centrosome | cellular component | A structure comprised of a core structure (in most organisms, a pair of centrioles) and peripheral material from which a microtubule-based structure, such as a spindle apparatus, is organized. Centrosomes occur close to the nucleus during interphase in many eukaryotic cells, though in animal cells it changes continually during the cell-division cycle. [GOC:mah, ISBN:0198547684] |
cytosol | cellular component | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. [GOC:hjd, GOC:jl] |
plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
apical plasma membrane | cellular component | The region of the plasma membrane located at the apical end of the cell. [GOC:curators] |
Active In
This protein is active in 3 target(s):
Target | Category | Definition |
cytosol | cellular component | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. [GOC:hjd, GOC:jl] |
nucleus | cellular component | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. [GOC:go_curators] |
perinuclear region of cytoplasm | cellular component | Cytoplasm situated near, or occurring around, the nucleus. [GOC:jid] |
Part Of
This protein is part of 2 target(s):
Target | Category | Definition |
voltage-gated calcium channel complex | cellular component | A protein complex that forms a transmembrane channel through which calcium ions may pass in response to changes in membrane potential. [GOC:mah] |
calcium channel complex | cellular component | An ion channel complex through which calcium ions pass. [GOC:mah] |
Involved In
This protein is involved in 18 target(s):
Target | Category | Definition |
regulation of heart rate | biological process | Any process that modulates the frequency or rate of heart contraction. [GOC:dph, GOC:tb, PMID:10358008] |
cAMP catabolic process | biological process | The chemical reactions and pathways resulting in the breakdown of the nucleotide cAMP (cyclic AMP, adenosine 3',5'-cyclophosphate). [ISBN:0198506732] |
positive regulation of heart rate | biological process | Any process that activates or increases the frequency or rate of heart contraction. [GOC:dph, GOC:tb] |
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | biological process | Any process that modulates the rate, frequency or extent of release of sequestered calcium ion into cytosol by the sarcoplasmic reticulum, the process in which the release of sequestered calcium ion by sarcoplasmic reticulum into cytosol occurs via calcium release channels. [GOC:BHF, GOC:dph, GOC:tb] |
positive regulation of type II interferon production | biological process | Any process that activates or increases the frequency, rate, or extent of interferon-gamma production. Interferon-gamma is also known as type II interferon. [GOC:add, GOC:mah, PMID:15546383] |
positive regulation of interleukin-2 production | biological process | Any process that activates or increases the frequency, rate, or extent of interleukin-2 production. [GOC:mah] |
positive regulation of interleukin-5 production | biological process | Any process that activates or increases the frequency, rate, or extent of interleukin-5 production. [GOC:mah] |
negative regulation of peptidyl-serine phosphorylation | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of the phosphorylation of peptidyl-serine. [GOC:mah] |
negative regulation of heart contraction | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of heart contraction. [GOC:go_curators] |
T cell receptor signaling pathway | biological process | The series of molecular signals initiated by the cross-linking of an antigen receptor on a T cell. [GOC:add] |
establishment of endothelial barrier | biological process | The establishment of a barrier between endothelial cell layers, such as those in the brain, lung or intestine, to exert specific and selective control over the passage of water and solutes, thus allowing formation and maintenance of compartments that differ in fluid and solute composition. [GOC:dph] |
adrenergic receptor signaling pathway | biological process | A G protein-coupled receptor signaling pathway initiated by a ligand binding to an adrenergic receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process. [GOC:BHF] |
regulation of cardiac muscle cell contraction | biological process | Any process that modulates the frequency, rate or extent of cardiac muscle cell contraction. [GOC:BHF, GOC:mtg_cardiac_conduct_nov11] |
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway | biological process | Any process that stops, prevents or reduces the frequency, rate or extent of an adenylate cyclase-activating G protein-coupled receptor signaling pathway. [GOC:hjd, PMID:19246489] |
regulation of cell communication by electrical coupling involved in cardiac conduction | biological process | Any process that modulates the frequency, rate or extent of cell communication by electrical coupling involved in cardiac conduction. [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:17130302] |
negative regulation of relaxation of cardiac muscle | biological process | Any process that stops, prevents or reduces the frequency, rate or extent of relaxation of cardiac muscle. [GOC:BHF, GOC:rl, GOC:TermGenie, PMID:19708671] |
regulation of calcium ion transmembrane transport via high voltage-gated calcium channel | biological process | Any process that modulates the frequency, rate or extent of generation of calcium ion transmembrane transport via high voltage-gated calcium channel. [GOC:dph, GOC:pg, GOC:TermGenie, PMID:1611048] |
cAMP-mediated signaling | biological process | An intracellular signaling cassette that starts with production of cyclic AMP (cAMP), and ends with activation of downstream effectors that further transmit the signal within the cell. [GOC:signaling] |